Increased mortality after successful treatment for Hodgkin's disease

Melissa M. Hudson, Catherine A. Poquette, Ji Lee, Carol A. Greenwald, Amit Shah, Xiaolong Luo, Elizabeth I. Thompson, Judith A. Wilimas, Larry E. Kun, William M. Crist

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Purpose: To determine the impact of treatment toxicity on long-term survival in pediatric Hodgkin's disease. Patients and Methods: We studied late events in 387 patients treated for pediatric Hodgkin's disease on four consecutive clinical trials at St Jude Children's Research Hospital from 1968 to 1990. Relative risks, actuarial risks, and absolute excess risks for cause-specific deaths were calculated. Results: As of April 1997, 316 (82%) of patients were alive, with a median follow-up of 15.1 (range, 2.9 to 28.6) years. In this cohort, which represented 5,623 person-years of follow-up, 71 fatal events resulted from Hodgkin's disease (n = 36), second malignancies (n = 14), infections (n = 7), accidents (n = 7), cardiac disease (n = 6), and asphyxiation (n = 1). The 5-year estimated event-free survival (EFS) for the entire cohort was 79.6% ± 2.1%, which declined to 63.1% ± 4.4% by 20 years. Cumulative incidences of cause-specific deaths at 25 years were 9.8% ± 1.6% for Hodgkin's disease, 8.1% ± 2.6% for second malignancy, 4.0% ± 1.8% for cardiac disease, 3.9% ± 1.5% for infection, and 2.1% ± 0.8% for accidents. Standardized incidence ratios showed excess risk for all second malignancies (12; 95% confidence interval [CI], 8 to 17), acute myeloid leukemia (81; 95% CI, 16 to 237), solid tumors (11; 95% CI, 7 to 16), and breast cancer (33; 95% CI, 12 to 72). Standardized mortality ratios also showed excess mortality from cardiac disease (22; 95% CI, 8 to 48) and infection (18; 95% CI, 7 to 38). Conclusion: Compared with age- and sex-matched control populations, survivors of pediatric Hodgkin's disease who were treated before 1990 face an increased risk of early mortality related to second cancers, cardiac disease, and infection.

Original languageEnglish (US)
Pages (from-to)3592-3600
Number of pages9
JournalJournal of Clinical Oncology
Volume16
Issue number11
DOIs
StatePublished - Jan 1 1998

Fingerprint

Hodgkin Disease
Second Primary Neoplasms
Confidence Intervals
Mortality
Heart Diseases
Pediatrics
Infection
Accidents
Cause of Death
Therapeutics
Asphyxia
Incidence
Acute Myeloid Leukemia
Disease-Free Survival
Survivors
Clinical Trials
Breast Neoplasms
Survival
Research
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hudson, M. M., Poquette, C. A., Lee, J., Greenwald, C. A., Shah, A., Luo, X., ... Crist, W. M. (1998). Increased mortality after successful treatment for Hodgkin's disease. Journal of Clinical Oncology, 16(11), 3592-3600. https://doi.org/10.1200/JCO.1998.16.11.3592

Increased mortality after successful treatment for Hodgkin's disease. / Hudson, Melissa M.; Poquette, Catherine A.; Lee, Ji; Greenwald, Carol A.; Shah, Amit; Luo, Xiaolong; Thompson, Elizabeth I.; Wilimas, Judith A.; Kun, Larry E.; Crist, William M.

In: Journal of Clinical Oncology, Vol. 16, No. 11, 01.01.1998, p. 3592-3600.

Research output: Contribution to journalArticle

Hudson, MM, Poquette, CA, Lee, J, Greenwald, CA, Shah, A, Luo, X, Thompson, EI, Wilimas, JA, Kun, LE & Crist, WM 1998, 'Increased mortality after successful treatment for Hodgkin's disease', Journal of Clinical Oncology, vol. 16, no. 11, pp. 3592-3600. https://doi.org/10.1200/JCO.1998.16.11.3592
Hudson MM, Poquette CA, Lee J, Greenwald CA, Shah A, Luo X et al. Increased mortality after successful treatment for Hodgkin's disease. Journal of Clinical Oncology. 1998 Jan 1;16(11):3592-3600. https://doi.org/10.1200/JCO.1998.16.11.3592
Hudson, Melissa M. ; Poquette, Catherine A. ; Lee, Ji ; Greenwald, Carol A. ; Shah, Amit ; Luo, Xiaolong ; Thompson, Elizabeth I. ; Wilimas, Judith A. ; Kun, Larry E. ; Crist, William M. / Increased mortality after successful treatment for Hodgkin's disease. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 11. pp. 3592-3600.
@article{e814b35418cd4571bdec94d527a07970,
title = "Increased mortality after successful treatment for Hodgkin's disease",
abstract = "Purpose: To determine the impact of treatment toxicity on long-term survival in pediatric Hodgkin's disease. Patients and Methods: We studied late events in 387 patients treated for pediatric Hodgkin's disease on four consecutive clinical trials at St Jude Children's Research Hospital from 1968 to 1990. Relative risks, actuarial risks, and absolute excess risks for cause-specific deaths were calculated. Results: As of April 1997, 316 (82{\%}) of patients were alive, with a median follow-up of 15.1 (range, 2.9 to 28.6) years. In this cohort, which represented 5,623 person-years of follow-up, 71 fatal events resulted from Hodgkin's disease (n = 36), second malignancies (n = 14), infections (n = 7), accidents (n = 7), cardiac disease (n = 6), and asphyxiation (n = 1). The 5-year estimated event-free survival (EFS) for the entire cohort was 79.6{\%} ± 2.1{\%}, which declined to 63.1{\%} ± 4.4{\%} by 20 years. Cumulative incidences of cause-specific deaths at 25 years were 9.8{\%} ± 1.6{\%} for Hodgkin's disease, 8.1{\%} ± 2.6{\%} for second malignancy, 4.0{\%} ± 1.8{\%} for cardiac disease, 3.9{\%} ± 1.5{\%} for infection, and 2.1{\%} ± 0.8{\%} for accidents. Standardized incidence ratios showed excess risk for all second malignancies (12; 95{\%} confidence interval [CI], 8 to 17), acute myeloid leukemia (81; 95{\%} CI, 16 to 237), solid tumors (11; 95{\%} CI, 7 to 16), and breast cancer (33; 95{\%} CI, 12 to 72). Standardized mortality ratios also showed excess mortality from cardiac disease (22; 95{\%} CI, 8 to 48) and infection (18; 95{\%} CI, 7 to 38). Conclusion: Compared with age- and sex-matched control populations, survivors of pediatric Hodgkin's disease who were treated before 1990 face an increased risk of early mortality related to second cancers, cardiac disease, and infection.",
author = "Hudson, {Melissa M.} and Poquette, {Catherine A.} and Ji Lee and Greenwald, {Carol A.} and Amit Shah and Xiaolong Luo and Thompson, {Elizabeth I.} and Wilimas, {Judith A.} and Kun, {Larry E.} and Crist, {William M.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1200/JCO.1998.16.11.3592",
language = "English (US)",
volume = "16",
pages = "3592--3600",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Increased mortality after successful treatment for Hodgkin's disease

AU - Hudson, Melissa M.

AU - Poquette, Catherine A.

AU - Lee, Ji

AU - Greenwald, Carol A.

AU - Shah, Amit

AU - Luo, Xiaolong

AU - Thompson, Elizabeth I.

AU - Wilimas, Judith A.

AU - Kun, Larry E.

AU - Crist, William M.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Purpose: To determine the impact of treatment toxicity on long-term survival in pediatric Hodgkin's disease. Patients and Methods: We studied late events in 387 patients treated for pediatric Hodgkin's disease on four consecutive clinical trials at St Jude Children's Research Hospital from 1968 to 1990. Relative risks, actuarial risks, and absolute excess risks for cause-specific deaths were calculated. Results: As of April 1997, 316 (82%) of patients were alive, with a median follow-up of 15.1 (range, 2.9 to 28.6) years. In this cohort, which represented 5,623 person-years of follow-up, 71 fatal events resulted from Hodgkin's disease (n = 36), second malignancies (n = 14), infections (n = 7), accidents (n = 7), cardiac disease (n = 6), and asphyxiation (n = 1). The 5-year estimated event-free survival (EFS) for the entire cohort was 79.6% ± 2.1%, which declined to 63.1% ± 4.4% by 20 years. Cumulative incidences of cause-specific deaths at 25 years were 9.8% ± 1.6% for Hodgkin's disease, 8.1% ± 2.6% for second malignancy, 4.0% ± 1.8% for cardiac disease, 3.9% ± 1.5% for infection, and 2.1% ± 0.8% for accidents. Standardized incidence ratios showed excess risk for all second malignancies (12; 95% confidence interval [CI], 8 to 17), acute myeloid leukemia (81; 95% CI, 16 to 237), solid tumors (11; 95% CI, 7 to 16), and breast cancer (33; 95% CI, 12 to 72). Standardized mortality ratios also showed excess mortality from cardiac disease (22; 95% CI, 8 to 48) and infection (18; 95% CI, 7 to 38). Conclusion: Compared with age- and sex-matched control populations, survivors of pediatric Hodgkin's disease who were treated before 1990 face an increased risk of early mortality related to second cancers, cardiac disease, and infection.

AB - Purpose: To determine the impact of treatment toxicity on long-term survival in pediatric Hodgkin's disease. Patients and Methods: We studied late events in 387 patients treated for pediatric Hodgkin's disease on four consecutive clinical trials at St Jude Children's Research Hospital from 1968 to 1990. Relative risks, actuarial risks, and absolute excess risks for cause-specific deaths were calculated. Results: As of April 1997, 316 (82%) of patients were alive, with a median follow-up of 15.1 (range, 2.9 to 28.6) years. In this cohort, which represented 5,623 person-years of follow-up, 71 fatal events resulted from Hodgkin's disease (n = 36), second malignancies (n = 14), infections (n = 7), accidents (n = 7), cardiac disease (n = 6), and asphyxiation (n = 1). The 5-year estimated event-free survival (EFS) for the entire cohort was 79.6% ± 2.1%, which declined to 63.1% ± 4.4% by 20 years. Cumulative incidences of cause-specific deaths at 25 years were 9.8% ± 1.6% for Hodgkin's disease, 8.1% ± 2.6% for second malignancy, 4.0% ± 1.8% for cardiac disease, 3.9% ± 1.5% for infection, and 2.1% ± 0.8% for accidents. Standardized incidence ratios showed excess risk for all second malignancies (12; 95% confidence interval [CI], 8 to 17), acute myeloid leukemia (81; 95% CI, 16 to 237), solid tumors (11; 95% CI, 7 to 16), and breast cancer (33; 95% CI, 12 to 72). Standardized mortality ratios also showed excess mortality from cardiac disease (22; 95% CI, 8 to 48) and infection (18; 95% CI, 7 to 38). Conclusion: Compared with age- and sex-matched control populations, survivors of pediatric Hodgkin's disease who were treated before 1990 face an increased risk of early mortality related to second cancers, cardiac disease, and infection.

UR - http://www.scopus.com/inward/record.url?scp=0031733382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031733382&partnerID=8YFLogxK

U2 - 10.1200/JCO.1998.16.11.3592

DO - 10.1200/JCO.1998.16.11.3592

M3 - Article

C2 - 9817280

AN - SCOPUS:0031733382

VL - 16

SP - 3592

EP - 3600

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -